Oral meptazinol--United Kingdom experience.
An oral formulation of meptazinol has been developed and marketed in the United Kingdom. The 200 mg tablet has a potency similar to dextropropoxyphene 32.5 mg/paracetamol 325 mg or pentazocine 50 mg. Nausea is the major side effect and constipation and dysphoria are virtually absent. Though a variable first pass metabolism restricts its potential for use in severe pain, oral meptazinol provides effective analgesia in mild or moderate pain.
D000082:Acetaminophen / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001381:Azepines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D011431:Dextropropoxyphene / Q000627:therapeutic use; D004311:Double-Blind Method; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D008621:Meptazinol / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D010146:Pain / Q000517:prevention & control; D010423:Pentazocine / Q000627:therapeutic use; D013607:Tablets
D001381:Azepines; D013607:Tablets; D008621:Meptazinol; D000082:Acetaminophen; D010423:Pentazocine; D011431:Dextropropoxyphene